NCT05284747: EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
- State
- Under way
- Phase
- Phase 4
- People
- 6,019 taking part
- Started
- 26 Oct 2022
- Primary completion
- 29 May 2027
- Arms
- Evolocumab + Routine Lipid Management
- Results
- None posted
- 17 Mar 2022: Trial registered
- 26 Oct 2022: Trial started